Site-specific controlled-release nanoparticles for immune reprogramming via dual metabolic inhibition against triple-negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Site-specific controlled-release nanoparticles for immune reprogramming via dual metabolic inhibition against triple-negative breast cancer

Published:2024-02 Issue: Volume:366 Page:204-220
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

She Wenyan,Li Haimei,Wang Zichen,Liu Tingting,Zhao Dongli,Guo Zhibin,Liu Yujiao,Liu Yi

Funder

Natural Science Foundation of Tianjin Municipality

Tianjin Municipal Science and Technology Committee

Natural Science Foundation of Tianjin Science and Technology Correspondent Project

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference51 articles.

1. Treatment of triple negative breast cancer (TNBC): current options and future perspectives;Laurentiis;Cancer Treat. Rev.,2010

2. Triple-negative breast cancer: the current aspects of pathogenesis and therapies;Mani;BioNanoScience,2022

3. Metabolic checkpoints and novel approaches for immunotherapy against cancer;Li;Int. J. Cancer,2022

4. Metabolic reprogramming in triple-negative breast cancer, Cancer;Wang;Biol. Med.,2020

5. DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer;Shen;Commun. Biol.,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancement in triple-negative breast cancer therapeutics: A comprehensive review on the potential of cell membrane-coated nanoparticles;Journal of Drug Delivery Science and Technology;2024-09

2. SAHA potentiates the activity of repurposed drug promethazine loaded PLGA nanoparticles in triple-negative breast cancer cells;Nanotechnology;2024-08-27

3. Recent advances in biomimetic cell membrane–camouflaged nanoparticles for cancer therapy;Biomedicine & Pharmacotherapy;2024-08

4. Strategic disruption of cancer’s powerhouse: precise nanomedicine targeting of mitochondrial metabolism;Journal of Nanobiotechnology;2024-06-08

5. Editorial: Overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine;Frontiers in Oncology;2024-04-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3